CEBPA mutation analysis

Alphabetical Test listing

CEBPA mutation analysis-13554

Test name:

Test number:

13554

Excellian order number:

LAB13554

Abbreviation:

CEBPA

Useful for:

The CEBPA (CCAAT/enhancer binding protein alpha) gene encodes a transcription factor important for granulocyte differentiation. CEBPA mutations are found in 6-15% of de novo acute myeloid leukemia (AML) and in 15-18% of AML with normal karyotypes. CEBPA mutations are associated with favorable prognosis in absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD). Germline CEBPA mutations are a cause of nonsyndromic, familial AML.

Specimen type:

EDTA whole blood

Collection container:

Lavender (EDTA), 4mL

Volume:

5 mL

Minimum volume:

3 mL

Collection instructions:

Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting

Transport container:

Lavender (EDTA), 4 mL

Alternate specimen type:

Sodium heparin (Na hep) whole blood
Bone marrow

Alternate collection container:

Dk green Sodium heparin (Na hep), no gel

Alternate specimen volume:

Bone marrow - 2 mL (minimum 1.0 mL)

Alternate collection instructions:

Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting

Alternate transport container:

Whole blood

Dk green Sodium heparin (Na hep), no gel

Bone marrow

Lavender (EDTA), 4mL

Dk green Sodium heparin (Na hep), no gel

Required forms/information:

Molecular Medicare billing request

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.

Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
All information requested is required in order for your request to be completed

Transport and stability:

Ambient (preferred)

Reason for rejection:

Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage.

Unsuitable specimens include but are not limited to:

frozen whole blood or marrow
a leaking tube
clotted blood or marrow
a grossly hemolyzed specimen or otherwise visibly degraded
specimen suspected of being contaminated by another specimen
specimen contains specific foreign material

Performing lab:

LabCorp RTP (489170): R-LC

Days set up:

Mo - Fr

TAT:

10 - 14 days

Method:

Polymerase chain reaction (PCR), direct sequencing and capillary electrophoresis

Reference ranges:

An interpretive report will be included

Preauthorization:

This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.

CPT codes:

81218

Subject to medical necessity (Y/N):

Yes

LOINC code:

Result 64012-8

Other billing information:

Medical necessity

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.

Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
All information requested is required in order for your request to be completed

Molecular Medicare billing request

Date created:

03/29/2019

Revised date:

10/05/2020

Review date:

01/02/2024